A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper

被引:8
|
作者
Laurens, Matthew B. [1 ]
Sirima, Sodiomon B. [2 ]
Rotrosen, Elizabeth T. [1 ,4 ]
Siribie, Mohamadou [2 ]
Tiono, Alfred [2 ]
Ouedraogo, Alphonse [2 ]
Liang, Yuanyuan [3 ]
Jamka, Leslie P. [1 ]
Kotloff, Karen L. [1 ]
Neuzil, Kathleen M. [1 ]
机构
[1] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, 685 W Baltimore St Room 480, Baltimore, MD 21201 USA
[2] Grp Rech Act Sante, Ouagadougou, Burkina Faso
[3] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA
[4] Boston Univ, Sch Med, Boston, MA 02215 USA
基金
比尔及梅琳达.盖茨基金会;
关键词
child; typhoid-paratyphoid vaccines; Burkina Faso; immunogenicity; conjugate; ACELLULAR PERTUSSIS-VACCINE; ENTERICA SEROVAR TYPHI; SUB-SAHARAN AFRICA; IMMUNE-RESPONSE; SALMONELLA; MULTICENTER;
D O I
10.1093/cid/ciy1104
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The recent Typhoid Fever Surveillance in Africa Program demonstrated an overall adjusted incidence of typhoid fever 2-3 times higher than previous estimates in Africa. Recently, a single-dose typhoid conjugate vaccine that allows infants as young as 6 months old to be vaccinated was prequalified by the World Health Organization (WHO). This Vi-based conjugate vaccine demonstrated robust immunogenicity after 1 dose in infants and children 6 through 23 months of age in India with no safety signal, and is currently being tested for the first time on the African continent in Malawi. The WHO Strategic Advisory Group of Experts recommends studies to evaluate co-administering Vi-typhoid conjugate vaccine (Vi-TCV) with routine childhood vaccines in typhoid-endemic countries. The Burkina Faso immunization schedule includes yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months, in addition to measles-rubella vaccine at both 9 and 15 months. Co-administration testing of Vi-TCV with these routine vaccinations will provide the data needed to support large-scale uptake of Vi-TCV in sub-Saharan Africa. A randomized, controlled, Phase II trial of Vi-TCV co-administration with the vaccinations routinely given at 9 and 15 months of age is planned in Burkina Faso. The overall aim is to assess the safety and immunogenicity of Vi-TCV when co-administered with YFV at 9 months of age and with MCV-A at 15 months of age. A total of 250 participants (100 infants aged 9-11 months and 150 children aged 15-23 months) will be enrolled. Clinical Trials Registration. NCT03614533. The World Health Organization recently prequalified a single-dose, typhoid conjugate vaccine for children as young as 6 months of age. A randomized, controlled clinical trial will assess the safety and immunogenicity of co-administration with routine childhood vaccines in Burkina Faso.
引用
收藏
页码:S59 / S66
页数:8
相关论文
共 50 条
  • [31] Safety and Immunogenicity of a New Rotavirus-Inactivated Vaccine in the Chinese Adolescent Population: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial
    Liu, Yan
    Feng, Guangwei
    Wu, Jinyuan
    Liu, Xinling
    Pu, Jing
    Wang, Yanxia
    You, Wangyang
    Yin, Na
    Yi, Shan
    Tan, Jiebing
    Lin, Xiaochen
    Huang, Lili
    Gao, Jiamei
    Yu, Qingchuan
    Tong, Qiumeng
    Zhang, Yong
    Chen, Rong
    Hu, Xiaoqing
    Ye, Jun
    Kuang, Xiangjing
    Zhou, Yan
    Hu, Zhongyu
    Zhao, Dongyang
    Li, Hongjun
    VACCINES, 2025, 13 (04)
  • [32] Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, Phase I clinical trial
    Li, Yan-Ping
    Liang, Zheng-Lun
    Gao, Qiang
    Huang, Li-Rong
    Mao, Qun-Ying
    Wen, Shu-Qun
    Liu, Yan
    Yin, Wei-Dong
    Li, Rong-Cheng
    Wang, Jun-Zhi
    VACCINE, 2012, 30 (22) : 3295 - 3303
  • [33] Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: A randomized, double-blind, active-controlled phase 1 clinical trial
    Wang, Yanxia
    Zhang, Yuhui
    Wu, Haofei
    Huang, Lili
    Yu, Hailong
    Xie, Zhiqiang
    Zhang, Huiping
    Zhang, Wei
    Chen, Xiaofen
    Zhang, Huan
    Zhang, Hongdong
    Jia, Chunyu
    Xia, Shengli
    Wang, Shuai
    VACCINE, 2021, 39 (29) : 3871 - 3878
  • [34] Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial
    Overbo, Joakim
    Aziz, Asma
    Zaman, K.
    Clemens, John
    Julin, Cathinka Halle
    Qadri, Firdausi
    Stene-Johansen, Kathrine
    Biswas, Rajib
    Islam, Shaumik
    Bhuiyan, Taufiqur Rahman
    Haque, Warda
    Sandbu, Synne
    Elahee, Manzoor E.
    Ali, Mohammad
    Dembinski, Jennifer L.
    Dudman, Susanne
    VACCINE, 2023, 41 (05) : 1059 - 1066
  • [35] Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial
    Abarca, Katia
    Rey-Jurado, Emma
    Munoz-Durango, Natalia
    Vazquez, Yaneisi
    Soto, Jorge A.
    Galvez, Nicolas M. S.
    Valdes-Ferrada, Javier
    Iturriaga, Carolina
    Urzua, Marcela
    Borzutzky, Arturo
    Cerda, Jaime
    Villarroel, Luis
    Madrid, Victoria
    Gonzalez, Pablo A.
    Gonzalez-Aramundiz, Jose, V
    Bueno, Susan M.
    Kalergis, Alexis M.
    ECLINICALMEDICINE, 2020, 27
  • [36] Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China
    Zhang, Yang
    Wang, Shiyuan
    Li, Guifan
    Shi, Jinhui
    Chang, Xianyun
    Zhang, Hao
    Zhu, Fengcai
    Li, Jingxin
    Pan, Hongxing
    Sun, Jinfang
    EXPERT REVIEW OF VACCINES, 2025, 24 (01) : 157 - 164
  • [37] Immunogenicity, antibody persistence, and safety of the 60g hepatitis B vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial
    Feng, Yongliang
    Shi, Xiaohong
    Shi, Jing
    Gao, Linying
    Liu, Guangming
    Cheng, Yanpeng
    Pan, Minghu
    Li, Chunxia
    Wang, Jun
    Guo, Xuxia
    Zhang, Yawei
    Liang, Xiaofeng
    Wang, Suping
    EXPERT REVIEW OF VACCINES, 2017, 16 (10) : 1045 - 1052
  • [38] Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study
    Huang, Lili
    Chen, Zhen
    Song, Yufei
    Tan, Jiebing
    Jia, Ningning
    You, Wangyang
    Yuan, Hongxue
    Feng, Guangwei
    Li, Changgui
    Luan, Chunfang
    Quan, Yaru
    Wang, Yanxia
    VACCINE, 2024, 42 (02) : 396 - 401
  • [39] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18-55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial
    Ansarifar, Akram
    Farahani, Ramin Hamidi
    Rahjerdi, Ahmad Karimi
    Ahi, Mohammadreza
    Sheidaei, Ali
    Gohari, Kimiya
    Rahimi, Zahra
    Gholami, Fatemeh
    Basiri, Pouria
    Moradi, Milad
    Jahangiri, Arash
    Naderi, Kosar
    Ghasemi, Soheil
    Khatami, Pezhman
    Honari, Mohsen
    Khodaverdloo, Samane
    Shooshtari, Mohammad
    Azin, Hajar Mehr
    Moradi, Sohrab
    Shafaghi, Batool
    Allahyari, Hossein
    Monazah, Arina
    Poor, Ali Khodaei
    Bakhshande, Hooman
    Taghva, Zahra
    Nia, Mohammad Karimi
    Dodaran, Masoud Solaymani
    Foroughizadeh, Mohsen
    VACCINE: X, 2023, 15
  • [40] Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
    Zhu, Fengcai
    Huang, Ting
    Jin, Pengfei
    Zhang, Linglin
    Jin, Zhongqiang
    Zhang, Wenli
    Yuan, Dongya
    Wang, Zhong
    Deng, Yusong
    Li, Jiaxin
    Shen, Xiao
    Fu, Yongpan
    Li, Jian
    Yang, Xinjie
    Li, Jing
    Xie, Liangzhi
    VACCINES, 2025, 13 (01)